An open label, single arm Phase I study to evaluate the safety, tolerability, and
pharmacokinetics of LUCAR-20S CAR-T cells in relapsed or refractory CD20+ diffuse large
B-cell, follicular, mantle cell and small lymphocytic lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Collaborator:
Nanjing Legend Biotechnology Co.,Ltd.; The First Affiliated Hospital of USTC west district; Beijing Boren Hospital